Lars Boesgaard - Dec 4, 2023 Form 4 Insider Report for PDS Biotechnology Corp (PDSB)

Role: Chief Financial Officer
Signature: /s/ Lars Boesgaard
Stock symbol: PDSB
Transactions as of: Dec 4, 2023
Transactions value $: $0
Form type: 4
Date filed: 12/4/2023, 06:14 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PDSB	Employee Stock Option (Right to Buy)	Award	$0	+200K		$0.00	200K	Dec 4, 2023	Common Stock	200K	$5.28	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option was granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4) and the Issuer's 2019 Inducement Plan, as amended. The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on December 4, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Content

The option was granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4) and the Issuer's 2019 Inducement Plan, as amended. The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on December 4, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.